Merial Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Merial Limited - overview
Location
Duluth, GA, US
Primary Industry
Pharmaceuticals
About
Merial Limited is a prominent developer of veterinary pharmaceuticals, focusing on innovative solutions to enhance animal health and well-being. The company’s expertise lies in creating specialized products for livestock and pets. Merial Limited operates as a leading veterinary pharmaceutical company headquartered in Duluth, US. The company specializes in developing animal health products and was established through a merger of several entities in the veterinary field.
Details about the founder's previous ventures are not available. Merial is recognized for its strategic alignment in providing high-quality health solutions for pets and livestock, contributing significantly to the overall animal health market. Merial Limited offers a comprehensive range of veterinary pharmaceuticals aimed at improving animal health. Its portfolio includes advanced vaccines and medications that cater to the needs of both livestock and companion animals.
The products are designed to enhance health outcomes, with a focus on safety and efficacy for various species. Merial has established a strong presence in the animal health industry, serving veterinarians, pet owners, and livestock producers globally. Merial Limited generates revenue through the sale of its veterinary pharmaceutical products, including vaccines and medications. The company operates on a direct sales model, with transactions occurring primarily through veterinary practices and agricultural channels.
While specific financial figures are not disclosed, its business strategy emphasizes establishing long-term relationships with clients, which is critical for sustaining revenue growth in the competitive animal health market. Merial Limited plans to introduce new vaccine formulations and treatment options within the next two years to enhance its product offerings. The company aims to expand its market presence in emerging regions such as Asia and Africa by 2025. Recent funding will be utilized to support research and development of these new products as well as to strengthen marketing efforts in these targeted regions, ensuring that Merial continues to meet the evolving needs of the animal health sector.
Primary Industry
Pharmaceuticals
Sub Industries
Specialty Pharmaceuticals, Pharmaceutical Research & Development
Website
www.merial.com
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.